<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679807</url>
  </required_header>
  <id_info>
    <org_study_id>18625</org_study_id>
    <nct_id>NCT02679807</nct_id>
  </id_info>
  <brief_title>Effect of Probiotic on Rhinovirus Induced Colds</brief_title>
  <acronym>MK EPRIC</acronym>
  <official_title>Effect of Probiotic on Rhinovirus Induced Colds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danisco Sweeteners Oy</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind placebo controlled trial to evaluate the effect of a
      probiotic (Bl-04) on the occurrence of rhinovirus-associated common cold illness in the
      experimental rhinovirus challenge model. A previous study documented that Bl-04 has
      significant effects on the innate immune response in the nose and this study will be powered
      to assess whether these effects translate into a demonstrable clinical benefit. Volunteers
      will be given Bl-04 or placebo for 28 days then challenged with rhinovirus. The primary
      analysis will be on the proportion of volunteers who develop a rhinovirus associated illness
      in the two treatment groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Rhinovirus-associated Illness Episodes</measure>
    <time_frame>5 days</time_frame>
    <description>Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">380</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>Bifidobacterium lactis Bl-04</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sucrose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bifidobacterium animalis subsp. lactis Bl-04</intervention_name>
    <arm_group_label>Bifidobacterium lactis Bl-04</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sucrose</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        INCLUSION CRITERIA AT ENROLLMENT:

          -  Subject must be 18-60 years of age.

          -  Subject must read and sign a copy of the approved Consent Form

          -  Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to
             rhinovirus type 39

        INCLUSION CRITERIA AT DAY -28

        â€¢ Female subjects must be using an effective birth control method.

        INCLUSION CRITERIA AT CHALLENGE:

          -  Female subjects must be using an effective birth control method.

        Exclusion Criteria:

          -  Antibiotic use within 3 months prior to day -28

               -  Female subjects with a positive urine pregnancy screen

               -  History of use of probiotics in the preceding two weeks

               -  Current cancer diagnosis or immunosuppressive therapy in the last 6 months

               -  Any clinically significant abnormalities of the upper respiratory tract

               -  Any clinically significant acute or chronic respiratory illness

               -  Any clinically significant bleeding tendency by history

               -  Hypertension that requires treatment with antihypertensive medications

               -  History of angina or other clinically significant cardiac disease

               -  Any medical condition that in the opinion of the Principal Investigator is cause
                  for exclusion from the study

               -  History of regular use (more than 3 days in 7) of tobacco products within the
                  preceding two weeks

               -  History of drug or alcohol abuse in the 6 months preceding the study

        EXCLUSION CRITERIA AT CHALLENGE:

          -  Any upper respiratory infection or allergic rhinitis in the two weeks prior to the
             challenge

          -  Female subjects with positive pregnancy screen prior to challenge

          -  Any medical condition that in the opinion of the Principal Investigator is cause for
             exclusion from the study

          -  Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold or allergy preparation
             in the two weeks prior to the challenge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <results_first_submitted>March 3, 2020</results_first_submitted>
  <results_first_submitted_qc>March 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 17, 2020</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Ronald Turner, MD</investigator_full_name>
    <investigator_title>Professor, Department of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02679807/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02679807/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All volunteers who signed consent were considered enrolled in the study per UVA IRB policy. 334 of these 380 volunteers were randomized to treatment after pre-treatment screening was complete.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bifidobacterium Lactis Bl-04</title>
          <description>2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
Bifidobacterium animalis subsp. lactis Bl-04</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>sucrose
sucrose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="165"/>
                <participants group_id="P2" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="143"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bifidobacterium Lactis Bl-04</title>
          <description>2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
Bifidobacterium animalis subsp. lactis Bl-04</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>sucrose
sucrose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="165"/>
            <count group_id="B2" value="169"/>
            <count group_id="B3" value="334"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.3" spread="6.7"/>
                    <measurement group_id="B2" value="22.2" spread="6.0"/>
                    <measurement group_id="B3" value="22.2" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Rhinovirus-associated Illness Episodes</title>
        <description>Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.</description>
        <time_frame>5 days</time_frame>
        <population>Volunteers who were challenged with rhinovirus, completed the study period and did not have any evidence by PCR or serology of a viral infection with a virus other than the challenge virus</population>
        <group_list>
          <group group_id="O1">
            <title>Bifidobacterium Lactis Bl-04</title>
            <description>2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
Bifidobacterium animalis subsp. lactis Bl-04</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>sucrose
sucrose</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rhinovirus-associated Illness Episodes</title>
          <description>Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.</description>
          <population>Volunteers who were challenged with rhinovirus, completed the study period and did not have any evidence by PCR or serology of a viral infection with a virus other than the challenge virus</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Consent/screening through the final study visit on study day 21-28.</time_frame>
      <desc>For the purposes of this study using experimental rhinovirus infection, physical signs and symptoms that are expected to be associated with the common cold should not be reported as adverse events. The following physical signs and symptoms are expected to be associated with the common cold: nasal obstruction (nasal stuffiness), coryza (runny nose), sore throat, cough, sneezing, myalgia, headache, feverishness, chills, loss of appetite and malaise.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bifidobacterium Lactis Bl-04</title>
          <description>2*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier
Bifidobacterium animalis subsp. lactis Bl-04</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>sucrose
sucrose</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>achillles tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="165"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>oropharyngeal pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="165"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="51" subjects_affected="39" subjects_at_risk="165"/>
                <counts group_id="E2" events="38" subjects_affected="35" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>dysmenorrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="165"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="165"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="165"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Turner</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-981-9141</phone>
      <email>rbt2n@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

